[go: up one dir, main page]

WO2018132639A8 - Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid - Google Patents

Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid Download PDF

Info

Publication number
WO2018132639A8
WO2018132639A8 PCT/US2018/013453 US2018013453W WO2018132639A8 WO 2018132639 A8 WO2018132639 A8 WO 2018132639A8 US 2018013453 W US2018013453 W US 2018013453W WO 2018132639 A8 WO2018132639 A8 WO 2018132639A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
kits
ocp
prognosis
diagnosis
Prior art date
Application number
PCT/US2018/013453
Other languages
French (fr)
Other versions
WO2018132639A1 (en
Inventor
Charles Stephen FOSTER
Razzaque AHMED
Original Assignee
Foster Charles Stephen
Ahmed Razzaque
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foster Charles Stephen, Ahmed Razzaque filed Critical Foster Charles Stephen
Publication of WO2018132639A1 publication Critical patent/WO2018132639A1/en
Publication of WO2018132639A8 publication Critical patent/WO2018132639A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides methods of diagnosing ocular cicatricial pemphigoid (OCP) in a subject, by determining the level or concentration of autoantibodies that bind β4 integrin in a biological sample obtained from the subject. In embodiments, the concentration of anti-β4 integrin autoantibodies is determined using an ELISA. Methods of monitoring the course of OCP, methods of treating OCP, and kits for diagnosing OCP are also provided.
PCT/US2018/013453 2017-01-13 2018-01-12 Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid WO2018132639A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762446080P 2017-01-13 2017-01-13
US62/446,080 2017-01-13

Publications (2)

Publication Number Publication Date
WO2018132639A1 WO2018132639A1 (en) 2018-07-19
WO2018132639A8 true WO2018132639A8 (en) 2019-06-27

Family

ID=61226655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/013453 WO2018132639A1 (en) 2017-01-13 2018-01-12 Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid

Country Status (1)

Country Link
WO (1) WO2018132639A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115508554A (en) * 2022-10-13 2022-12-23 大连大学 A diagnostic kit for mucosal pemphigoid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
JPH08507926A (en) 1993-03-19 1996-08-27 シーケノム・インコーポレーテツド DNA sequencing by mass spectrometry via exonuclease degradation
WO2011160096A2 (en) * 2010-06-17 2011-12-22 Banyan Biomarkers, Inc. Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition

Also Published As

Publication number Publication date
WO2018132639A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
PH12019502558A1 (en) Diagnostic assays for detecting, quantifying, and/or tracking microbes and other analytes
WO2017070114A3 (en) Diabetes-related biomarkers and treatment of diabetes-related conditions
NZ782016A (en) Biomarkers of traumatic brain injury
EP4293358A3 (en) Volatile organic compounds as cancer biomarkers
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
MX341517B (en) Pancreatic cancer biomarkers and uses thereof.
MX2017003370A (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm.
WO2015095862A3 (en) Microrna biomarkers for ovarian cancer
BR112019005167A2 (en) method and kit for analyzing a sample
BR112022011676A2 (en) KIT TO DETECT AN ANALYTE OF INTEREST IN A PLURALITY OF BIOLOGICAL LIQUID SAMPLES, METHOD TO DETECT AND/OR QUANTIFY IT AND CARTRIDGE TO PERFORM SUCH METHOD
NZ729773A (en) Biomarkers for disease progression in melanoma
BR112019005172A2 (en) method and kit for analyzing a sample
SG10201806729VA (en) Novel assay to detect human periostin
WO2021053343A8 (en) Methods for predicting patient response to DMARDs
EP2937421A3 (en) Biomarker for predicting effect of an anti-C-met antibody
MX2019000591A (en) Improved low sample volume urinalysis assay strip, analytical kits, and methods of use related thereto.
GB2552271A (en) A method for diagnosing lung cancer
WO2015166353A3 (en) Early detection of preeclampsia
EP3502271A3 (en) Blood biomarkers for appendicitis and diagnostics methods using biomarkers
WO2018132639A8 (en) Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid
WO2021138273A3 (en) Autoantibodies as biomarkers for autoimmune polyglandular syndrome type 1
SG11201811433TA (en) Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method
NZ601643A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112019005179A2 (en) method and kit for analyzing a sample
EP3599288A3 (en) Diagnosis and treatment of psoriatic arthritis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18705514

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18705514

Country of ref document: EP

Kind code of ref document: A1